Skip to Content
Merck
All Photos(1)

Key Documents

1098184

USP

Ceftriaxone sodium

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Ceftriaxone disodium salt hemi(heptahydrate)

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C18H16N8Na2O7S3 · 3.5H2O
CAS Number:
Molecular Weight:
661.60
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

ceftriaxone

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O.O.O.O.O.O.O.[Na+].[Na+].CO\N=C(/C(=O)N[C@H]1C2SCC(CSC3=NC(=O)C(=O)N([Na])N3C)=C(N2C1=O)C([O-])=O)c4csc(N)n4.CO\N=C(/C(=O)N[C@H]5C6SCC(CSC7=NC(=O)C(=O)N([Na])N7C)=C(N6C5=O)C([O-])=O)c8csc(N)n8

InChI

1S/2C18H18N8O7S3.4Na.7H2O/c2*1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7;;;;;;;;;;;/h2*5,9,15H,3-4H2,1-2H3,(H5,19,20,21,23,27,29,31,32);;;;;7*1H2/q;;4*+1;;;;;;;/p-4/b2*24-8-;;;;;;;;;;;/t2*9-,15-;;;;;;;;;;;/m11.........../s1

InChI key

PMRZKYOXTPBIQF-MAODNAKNSA-J

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Ceftriaxone sodium USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Ceftriaxone for Injection
  • Ceftriaxone Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Pictograms

Health hazardExclamation mark

Signal Word

Danger

Hazard Statements

Hazard Classifications

Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael S Northrop et al.
Journal of pediatric hematology/oncology, 37(1), e63-e66 (2014-06-01)
Ceftriaxone is a frequently used empiric antibiotic in children. Acute hemolysis is a rare side effect of ceftriaxone therapy associated with a high mortality rate. A 14-year-old boy suffering from Crohn disease developed bacterial pneumonia that was treated with ceftriaxone.
A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia.
Monica M Lahra et al.
The New England journal of medicine, 371(19), 1850-1851 (2014-11-06)
Scott V Monte et al.
Expert opinion on drug safety, 7(5), 515-523 (2008-09-02)
Isolated reports of neonatal and infant deaths associated with ceftriaxone-calcium precipitation in the lungs and kidneys have prompted a recommendation from the US FDA in June 2007 advising that in patients of all ages, calcium-containing solutions should not be administered
Tatiana Barichello et al.
Journal of neuroimmunology, 272(1-2), 35-41 (2014-05-27)
Neonatal Escherichia coli meningitis continues to be an important cause of mortality and morbidity in newborns worldwide. The aim of this study was to investigate the cytokines/chemokines, brain-derived neurotrophic factor (BDNF) levels, blood-brain barrier integrity in neonatal rats following E.
Ning Li et al.
Pediatrics, 133(4), e917-e922 (2014-03-26)
Our aim was to evaluate the clinical profile, treatment, and outcome of ceftriaxone-associated postrenal acute renal failure (PARF) in children. We retrospectively studied 31 consecutive cases from 2003 to 2012 for PARF after ceftriaxone treatment. There was no past history

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service